1. Travel-associated Burkholderia pseudomallei infection (Melioidosis) in a patient with cystic fibrosis: a case report.
- Author
-
Visca P, Cazzola G, Petrucca A, and Braggion C
- Subjects
- Anti-Bacterial Agents therapeutic use, Burkholderia pseudomallei classification, Ceftazidime therapeutic use, Cephalosporins therapeutic use, DNA, Bacterial analysis, Drug Therapy, Combination, Female, Humans, Melioidosis complications, Melioidosis drug therapy, Molecular Sequence Data, RNA, Ribosomal, 16S genetics, Risk Factors, Thailand, Travel, Trimethoprim, Sulfamethoxazole Drug Combination therapeutic use, Cystic Fibrosis complications, Melioidosis etiology
- Abstract
In September 1997, a 25-year-old Italian woman with cystic fibrosis (CF) spent 3 weeks in Thailand. In August 1998, her pulmonary function rapidly declined, with productive cough and intermittent fever. Chest x-ray films revealed diffuse, small, patchy opacities in the upper lobes. Burkholderia pseudomallei (BP) was isolated from specimens of the patient's sputum and was identified by means of 16S rDNA sequencing. The diagnosis of melioidosis was serologically confirmed. Continuous therapy with ceftazidime and co-trimoxazole and maintenance with co-trimoxazole, doxycycline, and chloramphenicol resulted in eradication of BP. We present the issue of whether patients with CF represent a population particularly at risk for melioidosis.
- Published
- 2001
- Full Text
- View/download PDF